




# PHARMACEUTICAL 2018

Theravance Biopharma Inc.  
Rank 128 of 342





RealRate

# PHARMACEUTICAL 2018

## Theravance Biopharma Inc. Rank 128 of 342



The relative strengths and weaknesses of Theravance Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Theravance Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 100% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	378,749
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	62,552
Liabilities, Non-Current	0
Other Assets	52,494
Other Compr. Net Income	-480
Other Expenses	36,271
Other Liabilities	0
Other Net Income	4,959
Other Revenues	15,386
Property and Equipment	10,157
Research and Development	173,887
Selling, General and Administrative Expense	95,592

Output Variable	Value in 1000 USD
Assets	441,400
Liabilities	62,552
Expenses	305,750
Revenues	15,386
Stockholders Equity	378,848
Net Income	-285,405
Comprehensive Net Income	-285,645
Economic Capital Ratio	145%